Cargando…
Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer
Basal-like breast cancer (BLBC) accounts for approximately 15% of all breast cancer cases, and patients with BLBC have a low survival rate. Our previous study demonstrated that the KLF5 transcription factor promotes BLBC cell proliferation and tumor growth. In this study, we demonstrated that the hi...
Autores principales: | Kong, Yanjie, Ren, Wenlong, Fang, Huan, Shah, Naseer Ali, Shi, Yujie, You, Dingyun, Zhou, Chengang, Jiang, Dewei, Yang, Chuanyu, Liang, Huichun, Liu, Wenjin, Wang, Luzhen, Gan, Wenqiang, Wan, Xing, Li, Fubing, Li, Zhen, Chen, Ceshi, Xie, Ni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935240/ https://www.ncbi.nlm.nih.gov/pubmed/35342356 http://dx.doi.org/10.7150/ijbs.65322 |
Ejemplares similares
-
DNA damage chemotherapeutic drugs suppress basal-like breast cancer growth by down-regulating the transcription of the FOXO1-KLF5 axis
por: Cui, Qiuxia, et al.
Publicado: (2023) -
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013) -
HDACiDB: a database for histone deacetylase inhibitors
por: Murugan, Kasi, et al.
Publicado: (2015) -
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018) -
Targeting the KLF5-EphA2 axis can restrain cancer stemness and overcome chemoresistance in basal-like breast cancer
por: Zhao, Ping, et al.
Publicado: (2023)